Daiichi Sankyo Company, Limited (TYO: 4568)
Japan
· Delayed Price · Currency is JPY | Market Cap | 10.97T |
| Revenue (ttm) | 1.69T |
| Net Income (ttm) | 229.10B |
| Shares Out | 1.90B |
| EPS (ttm) | 119.45 |
| PE Ratio | 48.34 |
| Forward PE | 60.82 |
| Dividend | 60.00 (1.06%) |
| Ex-Dividend Date | Sep 27, 2024 |
| Volume | 5,450,400 |
| Open | 5,630.00 |
| Previous Close | 5,646.00 |
| Day's Range | 5,582.00 - 5,833.00 |
| 52-Week Range | 3,566.00 - 6,257.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi... [Read more]
Financial Performance
In 2023, Daiichi Sankyo Company's revenue was 1.60 trillion, an increase of 25.28% compared to the previous year's 1.28 trillion. Earnings were 200.73 billion, an increase of 83.84%.
Financial StatementsNews
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO.
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining...
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based on DESTINY-Breast06 phase 3 trial results Eleventh Breakthrough Therapy Designat...
Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global Corpo...
Daiichi Sankyo Opens New Affiliate for Oncology in Greece
ATHENS, Greece--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company's s...
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million ...
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue
Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the p...
Daiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
Hiroyuki Okuzawa, president and COO of the Japanese pharma company, discusses the company's results and growth projections.
Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2023 Earnings Call Transcript April 25, 2024 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Hiroyuki Okuza...
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript
U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final W...
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), annou...
Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery
PARIS--(BUSINESS WIRE)--Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader's RNA-targeted d...
Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH.
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo
A Japanese health ministry panel on Monday recommended approval for an updated version of Daiichi Sankyo's COVID-19 vaccine, the Kyodo news agency said.
Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine
Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine.
Change in Leadership at Daiichi Sankyo Europe
MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced the appointment of its new ...
Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion
Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in developmen...
Trending Tickers: AT&T, Merck-Daiichi Sankyo, Klaviyo: Trending tickers October 29, 2023
Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japanese pharmaceutical company Daiichi Sankyo (4568.T)...
Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion
Drugmaker Merck (MRK) agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of the Japanese company's candidate cancer drugs.
Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly develop and commercialize three cancer drug candida...
Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates
Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates, the companies said on Thursday.
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in multiple types of cancer at the 2023 Europ...
EU recommends approval of AstraZeneca and Daiichi's drug for a type of lung cancer
AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a monotherapy to treat patient with a type of non-small cell l...